Disc Medicine, Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Disc Medicine's CEO to present at the J.P. Morgan Healthcare Conference on January 14, 2026, via webcast.

Quiver AI Summary

Disc Medicine, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases, announced that its CEO, John Quisel, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will be available via a live webcast and later as an archived replay on the company’s investor relations website. Disc Medicine is dedicated to creating potentially first-in-class therapies targeting critical biological pathways related to red blood cell biology, including heme biosynthesis and iron homeostasis. For further information, the company’s website can be visited.

Potential Positives

Disc Medicine's participation in the prestigious J.P. Morgan Healthcare Conference highlights the company's visibility and credibility in the biopharmaceutical industry.
The live webcast of the corporate presentation allows for broad access to investors and stakeholders, promoting transparency and engagement.
John Quisel's leadership as President and CEO in presenting at a significant industry event underscores the company's commitment to communicate its vision and developments effectively.
The company's focus on novel treatments for serious hematologic diseases positions it as an innovator in a niche market with critical unmet needs.

Potential Negatives

None

FAQ

When is Disc Medicine's presentation at the J.P. Morgan Healthcare Conference?

Disc Medicine's presentation will take place on Wednesday, January 14th, at 3:00 pm PT / 6:00 pm ET.

How can I watch the webcast of the presentation?

The live webcast will be available through the investor relations section of Disc Medicine's website at ir.discmedicine.com.

What is Disc Medicine focused on?

Disc Medicine is focused on discovering and developing novel treatments for serious hematologic diseases.

What types of diseases does Disc Medicine target?

Disc Medicine targets a wide spectrum of hematologic diseases through therapies aimed at heme biosynthesis and iron homeostasis.

Who will present at the conference?

John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc Medicine, will present at the conference.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$IRON Insider Trading Activity

$IRON insiders have traded $IRON stock on the open market 73 times in the past 6 months. Of those trades, 0 have been purchases and 73 have been sales.

Here’s a breakdown of recent trading of $IRON stock by insiders over the last 6 months:

DMI LLC AI sold 744,047 shares for an estimated $59,873,462
KEVIN BITTERMAN has made 0 purchases and 54 sales selling 455,344 shares for an estimated $36,590,629.
JOHN D QUISEL (Chief Executive Officer) has made 0 purchases and 6 sales selling 74,800 shares for an estimated $5,647,456.
JONATHAN YEN-WEN YU (Chief Operating Officer) has made 0 purchases and 4 sales selling 30,000 shares for an estimated $2,540,922.
WILLIAM JACOB SAVAGE (Chief Medical Officer) has made 0 purchases and 3 sales selling 13,093 shares for an estimated $1,194,372.
RAHUL KHARA (Chief Legal Officer) has made 0 purchases and 3 sales selling 6,500 shares for an estimated $511,471.
JEAN M. FRANCHI (Chief Financial Officer) has made 0 purchases and 2 sales selling 4,031 shares for an estimated $234,829.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$IRON Hedge Fund Activity

We have seen 87 institutional investors add shares of $IRON stock to their portfolio, and 53 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 1,689,449 shares (+52.1%) to their portfolio in Q3 2025, for an estimated $111,638,789
JANUS HENDERSON GROUP PLC removed 1,192,257 shares (-76.7%) from their portfolio in Q3 2025, for an estimated $78,784,342
PARADIGM BIOCAPITAL ADVISORS LP removed 963,255 shares (-79.5%) from their portfolio in Q3 2025, for an estimated $63,651,890
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC removed 583,500 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $38,557,680
VESTAL POINT CAPITAL, LP added 360,000 shares (+257.1%) to their portfolio in Q3 2025, for an estimated $23,788,800
BALYASNY ASSET MANAGEMENT L.P. added 338,101 shares (+inf%) to their portfolio in Q3 2025, for an estimated $22,341,714
GOLDMAN SACHS GROUP INC added 303,225 shares (+134.3%) to their portfolio in Q3 2025, for an estimated $20,037,108

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$IRON Analyst Ratings

Wall Street analysts have issued reports on $IRON in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Wells Fargo issued a "Overweight" rating on 12/16/2025
Truist Securities issued a "Buy" rating on 11/10/2025
Stifel issued a "Buy" rating on 11/03/2025
Morgan Stanley issued a "Overweight" rating on 10/30/2025
Wedbush issued a "Outperform" rating on 10/17/2025
Cantor Fitzgerald issued a "Overweight" rating on 10/17/2025

To track analyst ratings and price targets for $IRON, check out Quiver Quantitative's $IRON forecast page.

$IRON Price Targets

Multiple analysts have issued price targets for $IRON recently. We have seen 7 analysts offer price targets for $IRON in the last 6 months, with a median target of $114.0.

Here are some recent targets:

Derek Archila from Wells Fargo set a target price of $109.0 on 12/16/2025
Danielle Brill from Truist Securities set a target price of $114.0 on 11/10/2025
Stephen Willey from Stifel set a target price of $125.0 on 11/03/2025
Sean Laaman from Morgan Stanley set a target price of $115.0 on 10/30/2025
Kristen Kluska from Cantor Fitzgerald set a target price of $153.0 on 10/17/2025
David Nierengarten from Wedbush set a target price of $110.0 on 10/17/2025
Michael Freeman from Raymond James set a target price of $108.0 on 10/17/2025

Full Release

WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the 44 ^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14 ^th at 3:00 pm PT / 6:00 pm ET.

A live webcast of the presentation will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com .

Media Contact

Peg Rusconi
Deerfield Group
[email protected]

Investor Relations Contact

Christina Tartaglia
Precision AQ
[email protected]